

Takashi Matsuzaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5218908/publications.pdf>

Version: 2024-02-01

67
papers

3,182
citations

201674

27
h-index

161849

54
g-index

68
all docs

68
docs citations

68
times ranked

4958
citing authors

#	ARTICLE	IF	CITATIONS
1	Morphological and functional adaptation of pancreatic islet blood vessels to insulin resistance is impaired in diabetic db/db mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166339.	3.8	4
2	Intestinal microbe-dependent 13 lipid metabolite 1-KetoA prevents inflammatory diseases in mice and cynomolgus macaques. <i>Mucosal Immunology</i> , 2022, 15, 289-300.	6.0	16
3	Predictive ability of current machine learning algorithms for type2 diabetes mellitus: A meta-analysis. <i>Journal of Diabetes Investigation</i> , 2022, 13, 900-908.	2.4	16
4	CREBH regulation of lipid metabolism through multifaceted functions that improve arteriosclerosis. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1129-1131.	2.4	0
5	Enterohepatic Transcription Factor CREB3L3 Protects Atherosclerosis via SREBP Competitive Inhibition. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 949-971.	4.5	11
6	Role of fatty acid elongase Elovl6 in the regulation of energy metabolism and pathophysiological significance in diabetes. <i>Diabetology International</i> , 2021, 12, 68-73.	1.4	22
7	Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in NonAlcoholic steatohepatitis model. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 800-810.	2.8	9
8	Macrophages rely on extracellular serine to suppress aberrant cytokine production. <i>Scientific Reports</i> , 2021, 11, 11137.	3.3	16
9	Starvation-induced transcription factor CREBH negatively governs body growth by controlling GH signaling. <i>FASEB Journal</i> , 2021, 35, e21663.	0.5	6
10	CtBP2 confers protection against oxidative stress through interactions with NRF1 and NRF2. <i>Biochemical and Biophysical Research Communications</i> , 2021, 562, 146-153.	2.1	5
11	Rapid manipulation of mitochondrial morphology in a living cell with iCMM. <i>Cell Reports Methods</i> , 2021, 1, 100052.	2.9	10
12	Serum lactate dehydrogenase level as a possible predictor of treatment preference in psoriasis. <i>Journal of Dermatological Science</i> , 2021, 103, 109-115.	1.9	5
13	High protein diet-induced metabolic changes are transcriptionally regulated via KLF15-dependent and independent pathways. <i>Biochemical and Biophysical Research Communications</i> , 2021, 582, 35-42.	2.1	6
14	The transcriptional corepressor CtBP2 serves as a metabolite sensor orchestrating hepatic glucose and lipid homeostasis. <i>Nature Communications</i> , 2021, 12, 6315.	12.8	12
15	ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. <i>Oncology Reports</i> , 2021, 47, .	2.6	17
16	FoxO-KLF15 pathway switches the flow of macronutrients under the control of insulin. <i>IScience</i> , 2021, 24, 103446.	4.1	6
17	Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide AcylChain Length and Hepatic Insulin Sensitivity in Mice. <i>Hepatology</i> , 2020, 71, 1609-1625.	7.3	44
18	Transcriptional co-repressor CtBP2 orchestrates epithelial-mesenchymal transition through a novel transcriptional holocomplex with OCT1. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 354-360.	2.1	12

#	ARTICLE	IF	CITATIONS
19	Advanced Oxidation Protein Products Contribute to Renal Tubulopathy via Perturbation of Renal Fatty Acids. <i>Kidney</i> 360, 2020, 1, 781-796.	2.1	6
20	CREBH Improves Diet-Induced Obesity, Insulin Resistance, and Metabolic Disturbances by FGF21-Dependent and FGF21-Independent Mechanisms. <i>IScience</i> , 2020, 23, 100930.	4.1	12
21	New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease. <i>Journal of Diabetes Investigation</i> , 2020, 11, 532-534.	2.4	21
22	Glucocorticoid receptor suppresses gene expression of Rev-erb α (Nr1d1) through interaction with the CLOCK complex. <i>FEBS Letters</i> , 2019, 593, 423-432.	2.8	21
23	Octacosanol and policosanols prevent high-fat diet-induced obesity and metabolic disorders by activating brown adipose tissue and improving liver metabolism. <i>Scientific Reports</i> , 2019, 9, 5169.	3.3	31
24	Rho-associated, coiled-coil-containing protein kinase 1 as a new player in the regulation of hepatic lipogenesis. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1165-1167.	2.4	4
25	Saturated Fatty Acids Undergo Intracellular Crystallization and Activate the NLRP3 Inflammasome in Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 744-756.	2.4	104
26	Novel non-alcoholic steatohepatitis model with histopathological and insulin-resistant features. <i>Pathology International</i> , 2018, 68, 12-22.	1.3	17
27	A candidate functional SNP rs7074440 in TCF7L2 alters gene expression through FOS in hepatocytes. <i>FEBS Letters</i> , 2018, 592, 422-433.	2.8	9
28	Molecular association model of PPAR α and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARM α . <i>Biochemical and Biophysical Research Communications</i> , 2018, 499, 239-245.	2.1	47
29	Elovl6 regulates mechanical damage-induced keratinocyte death and skin inflammation. <i>Cell Death and Disease</i> , 2018, 9, 1181.	6.3	19
30	The Peroxisome Proliferator-Activated Receptor α (PPAR α) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2148.	4.1	43
31	Transgenic Mice Overexpressing SREBP-1a in Male ob/ob Mice Exhibit Lipodystrophy and Exacerbate Insulin Resistance. <i>Endocrinology</i> , 2018, 159, 2308-2323.	2.8	14
32	Evaluation of safety for hepatectomy in a novel mouse model with nonalcoholic-steatohepatitis. <i>World Journal of Gastroenterology</i> , 2018, 24, 1622-1631.	3.3	7
33	Selective peroxisome proliferator-activated receptor α modulator K877 efficiently activates the peroxisome proliferator-activated receptor α pathway and improves lipid metabolism in mice. <i>Journal of Diabetes Investigation</i> , 2017, 8, 446-452.	2.4	34
34	Elovl6 Deficiency Improves Glycemic Control in Diabetic db/db Mice by Expanding β -Cell Mass and Increasing Insulin Secretory Capacity. <i>Diabetes</i> , 2017, 66, 1833-1846.	0.6	29
35	Effects of K-877, a novel selective PPAR α modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. <i>Journal of Pharmacological Sciences</i> , 2017, 133, 214-222.	2.5	36
36	A key role of nuclear factor Y in the refeeding response of fatty acid synthase in adipocytes. <i>FEBS Letters</i> , 2017, 591, 965-978.	2.8	15

#	ARTICLE	IF	CITATIONS
37	SREBP1 Contributes to Resolution of Pro-inflammatory TLR4 Signaling by Reprogramming Fatty Acid Metabolism. <i>Cell Metabolism</i> , 2017, 25, 412-427.	16.2	263
38	Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry. <i>Biochemical and Biophysical Research Communications</i> , 2017, 493, 40-45.	2.1	22
39	Crucial Role of Elovl6 in Chondrocyte Growth and Differentiation during Growth Plate Development in Mice. <i>PLoS ONE</i> , 2016, 11, e0159375.	2.5	8
40	Elongation of Long-Chain Fatty Acid Family Member 6 (Elovl6)-Driven Fatty Acid Metabolism Regulates Vascular Smooth Muscle Cell Phenotype Through AMP-Activated Protein Kinase/KrÄ¼ppel-Like Factor 4 (AMPK/KLF4) Signaling. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	31
41	CREB3L3 controls fatty acid oxidation and ketogenesis in synergy with PPARÎ±. <i>Scientific Reports</i> , 2016, 6, 39182.	3.3	45
42	KLF15 Enables Rapid Switching between Lipogenesis and Gluconeogenesis during Fasting. <i>Cell Reports</i> , 2016, 16, 2373-2386.	6.4	94
43	Intestinal CREBH overexpression prevents high-cholesterol diet-induced hypercholesterolemia by reducing Npc1l1 expression. <i>Molecular Metabolism</i> , 2016, 5, 1092-1102.	6.5	32
44	Novel role for the <scp>CRTC</scp>2 in lipid homeostasis. <i>Journal of Diabetes Investigation</i> , 2016, 7, 677-679.	2.4	4
45	Hyperlipidemia and hepatitis in liver-specific CREB3L3 knockout mice generated using a one-step CRISPR/Cas9 system. <i>Scientific Reports</i> , 2016, 6, 27857.	3.3	31
46	Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. <i>PLoS ONE</i> , 2016, 11, e0157580.	2.5	50
47	1,8-Cineole Ameliorates Steatosis of Pten Liver Specific KO Mice via Akt Inactivation. <i>International Journal of Molecular Sciences</i> , 2015, 16, 12051-12063.	4.1	27
48	Identification of human ELOVL5 enhancer regions controlled by SREBP. <i>Biochemical and Biophysical Research Communications</i> , 2015, 465, 857-863.	2.1	20
49	Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy. <i>Biochemical and Biophysical Research Communications</i> , 2015, 466, 536-540.	2.1	59
50	Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr ^{-/-} mouse model. <i>Scientific Reports</i> , 2015, 5, 17604.	3.3	20
51	New liver-Î²-cell axis that controls insulin secretory capacity. <i>Journal of Diabetes Investigation</i> , 2014, 5, 276-277.	2.4	2
52	Hepatic CREB3L3 Controls Whole-Body Energy Homeostasis and Improves Obesity and Diabetes. <i>Endocrinology</i> , 2014, 155, 4706-4719.	2.8	49
53	Ablation of Elovl6 protects pancreatic islets from high-fat diet-induced impairment of insulin secretion. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 318-323.	2.1	15
54	Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice. <i>Nature Communications</i> , 2013, 4, 2563.	12.8	77

#	ARTICLE	IF	CITATIONS
55	Insulinâ€dependent and â€independent regulation of sterol regulatory elementâ€binding proteinâ€1c. Journal of Diabetes Investigation, 2013, 4, 411-412.	2.4	14
56	Elovl6 promotes nonalcoholic steatohepatitis. Hepatology, 2012, 56, 2199-2208.	7.3	144
57	GLUT12: a second insulinâ€responsive glucose transporters as an emerging target for type 2 diabetes. Journal of Diabetes Investigation, 2012, 3, 130-131.	2.4	5
58	Molecular mechanisms involved in hepatic steatosis and insulin resistance. Journal of Diabetes Investigation, 2011, 2, 170-175.	2.4	62
59	Macrophage Elovl6 Deficiency Ameliorates Foam Cell Formation and Reduces Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1973-1979.	2.4	32
60	Elovl6: a new player in fatty acid metabolism and insulin sensitivity. Journal of Molecular Medicine, 2009, 87, 379-384.	3.9	135
61	Cholesterol accumulation and diabetes in pancreatic Î²-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. Journal of Lipid Research, 2008, 49, 2524-2534.	4.2	95
62	Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nature Medicine, 2007, 13, 1193-1202.	30.7	459
63	Granuphilin is activated by SREBP-1c and involved in impaired insulin secretion in diabetic mice. Cell Metabolism, 2006, 4, 143-154.	16.2	60
64	TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes. Nature Medicine, 2006, 12, 107-113.	30.7	168
65	Insulin-Independent Induction of Sterol Regulatory Element-Binding Protein-1c Expression in the Livers of Streptozotocin-Treated Mice. Diabetes, 2004, 53, 560-569.	0.6	167
66	Cloning and characterization of a mammalian fatty acyl-CoA elongase as a lipogenic enzyme regulated by SREBPs. Journal of Lipid Research, 2002, 43, 911-920.	4.2	172
67	Cloning and characterization of a mammalian fatty acyl-CoA elongase as a lipogenic enzyme regulated by SREBPs. Journal of Lipid Research, 2002, 43, 911-20.	4.2	133